Company intelligence / Profile preview

GenomeKey

Newent, England, United Kingdomgenomekey.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GenomeKey has developed a proven technology platform for rapid sepsis diagnostics. The system can identify bacterial species and their antibiotic resistance profile directly from patient blood within hours, aiming to reduce the time to targeted therapy from days to just four hours. The company is currently engaging with global healthcare partners to demonstrate clinical benefit in real-world settings. No published clinical trial results yet; technology is supported by non-dilutive funding including CARB-X grants.

Therapeutic areas: Infectious Diseases
Modalities: DeviceIn vitro diagnostic (IVD) device
Industry: Molecular Diagnostics

Partnerships

CARB-X (global non-profit supporting antimicrobial innovation)

Beyond the preview

Go deeper on GenomeKey.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenomeKey.

Explore the full profile